Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Short Interest Update

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the recipient of a significant increase in short interest in the month of February. As of February 13th, there was short interest totaling 111,873 shares, an increase of 450.6% from the January 29th total of 20,320 shares. Currently, 6.8% of the shares of the company are sold short. Based on an average daily volume of 293,075 shares, the short-interest ratio is presently 0.4 days. Based on an average daily volume of 293,075 shares, the short-interest ratio is presently 0.4 days. Currently, 6.8% of the shares of the company are sold short.

Catheter Precision Stock Up 1.8%

NYSEAMERICAN VTAK traded up $0.03 on Friday, hitting $1.66. 11,501 shares of the company’s stock were exchanged, compared to its average volume of 170,984. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.46 and a current ratio of 0.46. The firm’s 50-day moving average price is $1.87 and its two-hundred day moving average price is $2.27. Catheter Precision has a fifty-two week low of $1.14 and a fifty-two week high of $15.68.

Institutional Investors Weigh In On Catheter Precision

A hedge fund recently bought a new stake in Catheter Precision stock. Millennium Management LLC bought a new position in shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned approximately 2.08% of Catheter Precision as of its most recent filing with the SEC. 20.34% of the stock is owned by institutional investors and hedge funds.

Catheter Precision Company Profile

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.